Cabaletta Bio Inc (CABA)

• $4.36

  $4.90

  $4.37
  

  0.23%

  Downside

  Day's Volatility :11.02%

  Upside

  10.82%

  
• $3.47

  $26.35

  $4.37
  

  20.57%

  Downside

  52 Weeks Volatility :86.83%

  Upside

  83.42%

  

Returns

What analysts predicted

Upside of 424.03%

• Jennison Associates LLC

  11.35%

• BlackRock Inc

  9.74%

• T. Rowe Price Investment Management,Inc.

  7.94%

• Adage Capital Partners Gp LLC

  6.22%

• Alkeon Capital Management, LLC

  5.36%

• Fred Alger Management, LLC

  5.16%

cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un